Please assess the completion status of the following clinical trial:

Trial Title: Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe hyponatremia (Na \< 130 mmol/L) or~* symptomatic hyponatremia - Na \< 135 mmol/L for at least six hours with Glasgow Coma Scale \< 15~Exclusion Criteria:~* Enrollment in the NMH high-risk spine protocol. These patients receive large amounts of fluids, have rapid changes in electrolytes, and are typically corrected in 48 hours~* Expected death from any cause~* Known sensitivity or allergy to conivaptan~* Renal failure (baseline creatinine \> 1.5 mg/dL)~* Clinical diagnosis of hypovolemia, or by central venous pressure (CVP) \< 5 mm Hg if a central venous catheter is in place~* Concomitant use of potent inhibitors of cytochrome P-450 isoenzyme 3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir). These agents are not commonly used in the Neuro-ICU~* Clinical diagnosis of liver failure or insufficiency~* Pregnancy (must be excluded before entry)~* Lack of informed consent from the patient or a legally authorized representative (LAR)~* Use of intra-arterial vasodilators (e.g. verapamil, nicardipine) within 24 hours (e.g. for vasospasm after SAH)~* Concern by the Neuro-ICU pharmacist of a drug-drug interaction that would meaningfully impact care (the Neuro-ICU pharmacist will review the medication regimen before recruitment)~* Patients with a diagnosis of diabetes insipidus or treated with vasopressin, since these patients are already treated for abnormal free water balance~* Patients with congestive heart failure, since this is an approved use of the drug (these patients are typically not cared for in the Neuro-ICU)~* Age\<18 years (these patients are not cared for at NMH)~* Inclusion declined by the attending physician or consulting study nephrologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Conivaptan in addition to usual care at the discretion of the attending medical staff
- 2 (Type: NO_INTERVENTION): Usual care by the attending physician staff

Based on this trial design, predict the completion outcome and termination type (if applicable).